CRO earnings roundup: Big pharma picking up biotech slack?
Big pharma is driving demand for CROs, backed by promising pipelines and an ‘appetite to spend,’ says analyst.
Big pharma is driving demand for CROs, backed by promising pipelines and an ‘appetite to spend,’ says analyst.
The Swiss Agency for Therapeutic Products revises the test it uses to assess whether sartan medicines are contaminated with nitrosamines.